Contrasting LeMaitre Vascular (NASDAQ:LMAT) and Nyxoah (NASDAQ:NYXH)

Nyxoah (NASDAQ:NYXH) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Volatility and Risk

Nyxoah has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.

Earnings & Valuation

This table compares Nyxoah and LeMaitre Vascular”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$5.08 million	50.89	-$46.77 million	($1.87)	-5.55
LeMaitre Vascular	$193.48 million	11.19	$30.10 million	$1.83	52.63

LeMaitre Vascular has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

84.6% of LeMaitre Vascular shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by insiders. Comparatively, 10.8% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Nyxoah and LeMaitre Vascular, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	0	0	5	0	3.00
LeMaitre Vascular	0	2	6	1	2.89

Nyxoah presently has a consensus target price of $17.00, suggesting a potential upside of 63.93%. LeMaitre Vascular has a consensus target price of $94.57, suggesting a potential downside of 1.81%. Given Nyxoah’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Nyxoah is more favorable than LeMaitre Vascular.

Profitability

This table compares Nyxoah and LeMaitre Vascular’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-1,043.93%	-51.68%	-40.11%
LeMaitre Vascular	19.40%	13.15%	11.47%

Summary

LeMaitre Vascular beats Nyxoah on 10 of the 15 factors compared between the two stocks.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About LeMaitre Vascular

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient’s body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.